一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Recent Results in Cancer Research >>article

Recent Results in Cancer Research

Download PDF

Axitinib (AG-013736).

Published:1 January 2010 DOI: 10.1007/978-3-642-01222-8_3 PMID: 20072829
Ronan Joseph Kelly, Olivier Rixe

Abstract

The vascular endothelial growth factor (VEGF)/VEGF receptor tyrosine kinase (RTK) signaling pathway plays a pivotal role in tumor angiogenesis. Neovascularization promotes increased tumor cell proliferation, survival and metasasis. Many antiangiogenic agents including multi-RTK inhibitors are either approved or are undergoing testing in clinical trials. Axitinib is a potent and selective inhibitor of VEGF RTK 1, 2, and 3. This chapter discusses the stucture of axitinib as well as its toxicities and drug interactions. Important preclinical and clinical data for axitinib are presented including findings from phase II studies in many tumor types including malignant melanoma and renal, pancreatic, thyroid, breast, lung and colorectal carcinomas. Ongoing phase III studies in pancreatic and metastatic renal cell carcinoma will ultimately define the therapeutic role of this targeted agent.

Substances (4)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Axitinib 319460-85-0 C22H18N4OS 511 suppliers $7.00-$1764.00
HUMAN VEGF165 127464-60-2 NULL 223 suppliers $98.40-$908.00
VEGF Receptor 2 13 suppliers Inquiry
RTK TOTAL 7-PLEX 4 suppliers Inquiry

Similar articles

IF:4.6

Clinical pharmacology of axitinib.

Clinical Pharmacokinetics Ying Chen, Michael A Tortorici,etc Published: 1 September 2013
宜昌市| 孟津县| 东山县| 汉川市| 渑池县| 叙永县| 尚义县| 都昌县| 高雄市| 万宁市| 新安县| 罗山县| 航空| 天峨县| 将乐县| 丰顺县| 法库县| 黔西县| 墨江| 团风县| 高邮市| 高要市| 略阳县| 三都| 安庆市| 惠州市| 开鲁县| 依安县| 鄂尔多斯市| 花莲市| 浮梁县| 永吉县| 南投市| 永州市| 剑河县| 孝感市| 离岛区| 三台县| 江阴市| 扶风县| 吉首市|